Ishara Investments LP
Reported holdings as of Q2 2026, from 3 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC | ACAD | $10.4M | 410,000 | +5.03pp | 3q | +233.3%+$7.3M | |
| XERIS BIOPHARMA HOLDINGS INC | XERS | $9.7M | 1,230,000 | +1.53pp | 3q | +20.0%+$1.6M | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $8.2M | 143,500 | +1.65pp | 3q | +75.0%+$3.5M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $7.5M | 22,550 | -7.58pp | 3q | HELD | |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | $6.8M | 205,000 | +1.57pp | 3q | +17.6%+$1.0M | |
| AGIOS PHARMACEUTICALS INC | AGIO | $6.1M | 164,000 | - | new | NEW | |
| INSMED INC | INSM | $5.5M | 51,250 | - | new | NEW | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $5.4M | 143,500 | - | new | NEW | |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | $5.0M | 1,025,000 | +0.93pp | 3q | -16.7%-$994.2K | |
| VAXCYTE INC | PCVX | $4.8M | 82,000 | +0.34pp | 3q | +42.9%+$1.4M | |
| ANNEXON INC | ANNX | $4.7M | 820,000 | +2.53pp | 3q | +370.6%+$3.7M | |
| TRAVERE THERAPEUTICS INC | TVTX | $4.7M | 82,000 | +0.31pp | 2q | -25.9%-$1.6M | |
| TONIX PHARMACEUTICALS HLDG C | TNXP | $4.3M | 338,250 | - | new | NEW | |
| BRIDGEBIO PHARMA INC | BBIO | $4.3M | 57,400 | - | new | NEW | |
| AXSOME THERAPEUTICS INC | AXSM | $4.0M | 16,400 | -3.61pp | 2q | -60.0%-$6.0M | |
| CONTINEUM THERAPEUTICS INC | CTNM | $3.4M | 205,000 | +0.71pp | 2q | +44.4%+$1.0M | |
| LEXICON PHARMACEUTICALS INC | LXRX | $3.1M | 1,271,000 | +0.91pp | 3q | +40.9%+$885.6K | |
| KURA ONCOLOGY INC | KURA | $3.0M | 276,750 | - | new | NEW | |
| DBV TECHNOLOGIES S A | DBVT | $3.0M | 184,500 | +0.20pp | 2q | +80.0%+$1.3M | |
| GENMAB A/S | GMAB | $2.8M | 102,500 | -0.01pp | 3q | +25.0%+$563.1K | |
| CYTOKINETICS INC | CYTK | $2.8M | 32,800 | - | new | NEW | |
| MINERALYS THERAPEUTICS INC | MLYS | $2.8M | 102,500 | -0.07pp | 2q | +25.0%+$553.1K | |
| SILENCE THERAPEUTICS PLC | SLN | $2.4M | 55,350 | +1.09pp | 3q | -60.6%-$3.7M | |
| NUVATION BIO INC | NUVB | $2.1M | 369,000 | - | new | NEW | |
| WAVE LIFE SCIENCES LTD | WVE | $1.9M | 328,000 | - | new | NEW | |
| NEKTAR THERAPEUTICS | NKTR | $1.9M | 26,650 | - | new | NEW | |
| SCHOLAR ROCK HLDG CORP | SRRK | $1.7M | 30,750 | -1.43pp | 2q | -46.4%-$1.5M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $1.7M | 32,800 | - | new | NEW | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $1.5M | 5,125 | -0.47pp | 2q | HELD | |
| BEAM THERAPEUTICS INC | BEAM | $1.4M | 41,000 | -0.26pp | 3q | -28.6%-$562.8K | |
| SIONNA THERAPEUTICS INC | SION | $1.4M | 123,000 | -0.88pp | 2q | +150.0%+$810.3K | |
| ORIC PHARMACEUTICALS INC | ORIC | $1.3M | 123,000 | -0.25pp | 3q | +20.0%+$222.0K | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $1.3M | 36,900 | -0.20pp | 3q | HELD | |
| VERTEX PHARMACEUTICALS INC | VRTX | $1.2M | 2,460 | - | new | NEW | |
| ARS PHARMACEUTICALS INC | SPRY | $1.1M | 143,490 | - | new | NEW | |
| MONOPAR THERAPEUTICS INC | MNPR | $1.1M | 12,300 | - | new | NEW | |
| ERASCA INC | ERAS | $751.1K | 41,000 | - | new | NEW | |
| VERA THERAPEUTICS INC | VERA | $439.8K | 10,250 | -2.80pp | 2q | -87.5%-$3.1M | |
| IMMATICS N.V | IMTX | $311.5K | 30,750 | -1.20pp | 3q | -80.0%-$1.2M | |
| MEREO BIOPHARMA GROUP PLC | MREO | $244.2K | 768,750 | - | new | NEW | |
| GOSSAMER BIO INC | GOSS | $135.0K | 820,000 | -0.16pp | 2q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $136.1M | 100.0% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $136.1M | 41 | 16 | 13 | 8 | 11 | 51.0% | 45 |
| Q1 2026 | $105.6M | 36 | 17 | 10 | 9 | 19 | 54.0% | 45 |
| Q4 2025 | $87.5M | 38 | 0 | 0 | 0 | 0 | 55.9% | 48 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.